TY  - BOOK
AU  - Mollaeian, Arash
TI  - Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. [Review]
SN  - 1744-666X
PY  - 2020///
KW  - *Arthritis/ci [Chemically Induced]
KW  - *Immune Checkpoint Inhibitors/ae [Adverse Effects]
KW  - Arthritis/di [Diagnosis]
KW  - Arthritis/ep [Epidemiology]
KW  - Arthritis/th [Therapy]
KW  - Autoimmune Diseases/co [Complications]
KW  - Humans
KW  - Immune Checkpoint Inhibitors/pd [Pharmacology]
KW  - MedStar Georgetown University Hospital Residents
KW  - Journal Article
N2  - AREAS COVERED: In this review, the authors focus on ICI-IIA. Relevant articles were identified through PubMed searches, spanning 2010 to the present. The authors detail the current understanding of its pathogenesis, diagnostic evaluation, and management strategies; EXPERT OPINION: ICI-IIA is a complex irAE that we are just beginning to understand mechanistically and pathologically. It often presents later in the disease course than other irAEs and, due to various reasons, is under-recognized. In some patients, ICI-IIA may become a chronic disease, which distinguishes it from most irAEs that resolve after ICI discontinuation. Multiple important questions still demand further research including which patients may develop ICI-IIA? What are possible diagnostic and prognostic markers? Do anti-arthritis therapies interfere with the anti-tumor response? and when should steroid-sparing agents be initiated? Close collaboration and shared decision-making between oncologists, rheumatologists, and the patient are essential when managing this particular irAE; INTRODUCTION: Immune checkpoint inhibitors (ICIs) have proved to be groundbreaking in the field of oncology. However, immune system overactivation from ICIs has introduced a novel medical entity known as immune-related adverse events (irAEs), that can affect any organ or tissue. ICI-induced inflammatory arthritis (ICI-IIA) is the most common musculoskeletal irAE and can lead to significant morbidity and limitation in anti-cancer therapy
UR  - https://dx.doi.org/10.1080/1744666X.2020.1804362
ER  -